Kane Biotech Restarts Commercial Activities and Strengthens North American Management

Company enters 2026 with renewed business momentum and key commercial appointments in the U.S. and CanadaWINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces the resumption of commercial activities in both the United States and Canada for its revyve® Antimicrobial Wound Gel product line, alongside the appointment of two seasoned industry leaders to drive business development across North America. US FDA 510(k) cleared ...